GlassScriptPhysician profile
Audrey Bell
NPI 1578349742
$758.80
in general payments reported to CMS, 2019-2025
15 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $469 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $281.97 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $103.04 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $56.92 | 2024 | Arexvy, Shingrix |
| Amgen INC. | $53.51 | 2024 | Repatha, Otezla |
| Dexcom, INC. | $32.00 | 2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $31.37 | 2024-2025 | Contrave |
| Astellas Pharma US INC | $30.70 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $27.06 | 2025 | |
| Hologic Sales and Service, LLC | $25.96 | 2024 | Aptima |
| Lilly USA, LLC | $23.48 | 2024 | Zepbound, Mounjaro |
| Cmp Pharma, INC. | $23.13 | 2024 | Tadliq, Liqrev, Atorvaliq |
| Esperion Therapeutics, INC. | $20.34 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $17.48 | 2024 | |
| Merck Sharp & Dohme LLC | $16.19 | 2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Abbvie INC. | $15.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.